Immunology & Rheumatology Clinical Trials

Statistical methods in immunology & rheumatology trials

The methods these trials rely on most, based on the statistical analyses posted to ClinicalTrials.gov, with the tutorial that explains each one.

All immunology & rheumatology trials

1,062 results

• Rapid Infusion Of Immune Globulin Intravenous (IGIV) In Patients With ITP: Complete Statistical AnalysisIndependent statistical analysis of Rapid Infusion Of Immune Globulin Intravenous (IGIV) In Patients With ITP: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…Phase 2Results postedn = 8NCT00220727
• Rasburicase in Patients at High Risk for Tumor Lysis Syndrome (TLS) During Cycle-2: Complete Statistical AnalysisIndependent statistical analysis of Rasburicase in Patients at High Risk for Tumor Lysis Syndrome (TLS) During Cycle-2: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…Phase 2Results postedn = 55NCT01200485
• Rasburicase in Patients at Risk for Tumor Lysis Syndrome: Complete Statistical AnalysisIndependent statistical analysis of Rasburicase in Patients at Risk for Tumor Lysis Syndrome: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00628628).Phase 2Results postedn = 82NCT00628628
• RATE-RAIndependent statistical analysis of A Study on The Safety of Administering Rituximab at A More Rapid Rate in Patients With Rheumatoid Arthritis: primary endpoint results, effect estimate with confidence interval, sample-size planning…Phase 4Results postedn = 351NCT01382940
• Re-exposure Study of Pegloticase Intravenous (i.v.) in Symptomatic Gout Patients: Complete Statistical AnalysisIndependent statistical analysis of Re-exposure Study of Pegloticase Intravenous (i.v.) in Symptomatic Gout Patients: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00675103).Phase 3Results postedn = 7NCT00675103
• REACH 5Independent statistical analysis of Activity, Safety and Pharmacokinetics in Pediatric Subjects With Moderate and Severe Chronic Graft vs. Host Disease After Allogeneic Stem Cell Transplant: primary endpoint results, effect estimate with confidence…Phase 2Results postedn = 46NCT03774082
• REACT AsthmaIndependent statistical analysis of REACT Asthma (NCT06299306), a registry study evaluating asthma control using the Asthma Impairment and Risk Questionnaire (AIRQ®) over 12 months.n = 19NCT06299306
• Real-World Outcome of Adalimumab on Rheumatoid Arthritis Patients in China: Complete Statistical AnalysisIndependent statistical analysis of Real-World Outcome of Adalimumab on Rheumatoid Arthritis Patients in China: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02668640).Phase NAResults postedn = 55NCT02668640
• Rebif® Pregnancy Registry: Complete Statistical AnalysisIndependent statistical analysis of Rebif® Pregnancy Registry: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00338741).Phase NAResults postedn = 36NCT00338741
• REDIRECTIndependent statistical analysis of Phase II Study to Assess AFM13 in Patients With R/R CD30-positive T-cell Lymphoma or Transformed Mycosis Fungoides: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…Phase 2Results postedn = 108NCT04101331
• Reduced-Intensity Busulfan and Fludarabine With or Without Antithymocyte Globulin Followed by Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other Disease: Complete Statistical AnalysisIndependent statistical analysis of Reduced-Intensity Busulfan and Fludarabine With or Without Antithymocyte Globulin Followed by Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other Disease: primary endpoint results, effect…Phase 2Results postedn = 71NCT00448201
• Reduced-intensity, Related-donor Bone Marrow Transplantation Followed by High-dose Cyclophosphamide for Hematologic Cancers: Complete Statistical AnalysisIndependent statistical analysis of Reduced-intensity, Related-donor Bone Marrow Transplantation Followed by High-dose Cyclophosphamide for Hematologic Cancers: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…Phase 2Results postedn = 15NCT01135329
• REFLEXIONIndependent statistical analysis of Long-term Follow-Up of Patients Who Participated in Study 27025 (REFLEX): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00813709).Phase 3Results postedn = 402NCT00813709
• RELEASE MSS5Independent statistical analysis of Evaluation of the Effect of Nabiximols Oromucosal Spray on Clinical Measures of Spasticity in Participants With Multiple Sclerosis: primary endpoint results, effect estimate with confidence interval, sample-size planning…Phase 3Results postedn = 56NCT04984278
• REMAINIndependent statistical analysis of A Phase IV Study of Rebif ® 44mcg Administered Three Times Per Week by Subcutaneous Injection Compared With no Treatment in the Therapy of Relapsing Multiple Sclerosis After…Phase 4Results postedn = 30NCT01142466
• REMOVALIndependent statistical analysis of REducing With MetfOrmin Vascular Adverse Lesions in Type 1 Diabetes (REMOVAL): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…Phase 3Results postedn = 493NCT01483560
• REPLACE-BGIndependent statistical analysis of A Trial Comparing Continuous Glucose Monitoring With and Without Routine Blood Glucose Monitoring in Adults With Type 1 Diabetes: primary endpoint results, effect estimate with confidence interval, sample-size…Phase NAResults postedn = 226NCT02258373
• RISE-MIndependent statistical analysis of Radiotherapy With Immunotherapy for Systemic Effect in Myeloma (RISE-M): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03634800).Phase 2Results postedn = 6NCT03634800
• ROCKIIndependent statistical analysis of Real-World Outcome of Adalimumab on Rheumatoid Arthritis Patients in Taiwan: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02616380).Phase NAResults postedn = 100NCT02616380
• ROSEIndependent statistical analysis of A Study of Tocilizumab in Combination With DMARDs in Patients With Moderate to Severe Rheumatoid Arthritis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…Phase 3Results postedn = 619NCT00531817
• RSLV-132Independent statistical analysis of A Study of RSLV-132 in Subjects With Primary Sjogren's Syndrome: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03247686).Phase 2Results postedn = 28NCT03247686
• RVD LiteIndependent statistical analysis of Lenalidomide/Bortezomib/Dexamethasone for Multiple Myeloma (MM): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01782963).Phase 2Results postedn = 50NCT01782963
• RVDDIndependent statistical analysis of Combination Study of Revlimid®, Velcade® Dexamethasone and Doxil® (RVDD)for Newly Diagnosed Multiple Myeloma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…Phase 1/2Results postedn = 74NCT00724568
• SAILIndependent statistical analysis of Observational Study of Tildrakizumab in Patients With Moderate to Severe Plaque Psoriasis in Routine Clinical Practice: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…Phase NAResults postedn = 331NCT04203693
• SALPIndependent statistical analysis of Pilot Study to Determine Effects of Salsalate in Type 1 Diabetes and Painful Peripheral Neuropathy: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…Phase 2Results postedn = 8NCT01480297
• SARCAIndependent statistical analysis of Lansoprazole to Treat Children With Asthma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00442013).Phase 4Results postedn = 306NCT00442013
• SCNSL1Independent statistical analysis of High-dose Sequential Chemoimmunotherapy for B-cell Lymphomas With Central Nervous System Involvement: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…Phase 2Results postedn = 40NCT00801216
• SELECT-EARLYIndependent statistical analysis of A Study to Compare Upadacitinib (ABT-494) Monotherapy to Methotrexate (MTX) Monotherapy in Adults With Rheumatoid Arthritis (RA) Who Have Not Previously Taken Methotrexate: primary endpoint results, effect estimate…Phase 3Results postedn = 1,002NCT02706873
• SELECTSUNRISEIndependent statistical analysis of A Study to Compare Upadacitinib (ABT-494) to Placebo in Adults With Rheumatoid Arthritis (RA) Who Are on a Stable Dose of Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs (csDMARDs) and…Phase 2/3Results postedn = 197NCT02720523
• SensoryFLOIndependent statistical analysis of Effects of Acute Intermittent Hypoxia on Sensory Function in Healthy Adults: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…Phase NAResults postedn = 22NCT03283072
• SICAS-1Independent statistical analysis of Allergens in Inner-City Schools and Childhood Asthma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01756391).Phase NAResults postedn = 351NCT01756391
• SiyakhanaIndependent statistical analysis of Community Health Worker Training to Reduce Depression and Substance Use Stigma in TB/HIV Care in South Africa: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…Phase NAResults postedn = 82NCT05282173
• SLEIndependent statistical analysis of A Prospective Study of Cyclophosphamide in Systemic Lupus Erythematosus Treatment: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01689350).Phase NAResults postedn = 92NCT01689350
• SMA002Independent statistical analysis of A Clinical Study of the Performance of a Glucose Blinding Protein-Based Continuous Glucose Monitor (GBP CGM): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…Phase 2Results postedn = 16NCT01469715
• SPEEDIndependent statistical analysis of Patient Actor Training to Improve HIV Services for Adolescents in Kenya: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…Phase NAResults postedn = 24NCT02928900
• SPRING-2Independent statistical analysis of A Trial Comparing GSK1349572 50mg Once Daily to Raltegravir 400mg Twice Daily: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…Phase 3Results postedn = 828NCT01227824
• STAGEIndependent statistical analysis of A Study of Ocrelizumab Compared to Placebo in Patients With Active Rheumatoid Arthritis Continuing Methotrexate Treatment (STAGE): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…Phase 3Results postedn = 1,015NCT00406419
• SWIFT-1Independent statistical analysis of Placebo-controlled Efficacy and Safety Study of GSK3511294 (Depemokimab) in Participants With Severe Asthma With an Eosinophilic Phenotype: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…Phase 3Results postedn = 395NCT04719832
• SYGMA2Complete statistical analysis of SYGMA2, a randomized phase 3 trial evaluating as-needed budesonide/formoterol versus twice-daily budesonide with as-needed terbutaline in adults and adolescents with asthma.Phase 3Results postedn = 4,215NCT02224157
• T1GERIndependent statistical analysis of A Study of SIMPONI® to Arrest Beta-cell Loss in Type 1 Diabetes: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…Phase 2Results postedn = 84NCT02846545
• TALCIndependent statistical analysis of Asthma Clinical Research Network (ACRN) Trial - Tiotropium Bromide as an Alternative to Increased Inhaled Corticosteroid in Patients Inadequately Controlled on a Lower Dose of Inhaled Corticosteroid (TALC):…Phase 3Results postedn = 210NCT00565266
• TERIKIDSIndependent statistical analysis of Efficacy, Safety and Pharmacokinetics of Teriflunomide in Pediatric Patients With Relapsing Forms of Multiple Sclerosis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…Phase 3Results postedn = 166NCT02201108
• TESIndependent statistical analysis of Electric Stimulation of the Eye to Improve Vision After Trauma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02019927).Phase NAResults postedn = 97NCT02019927
• TIDE-asthmaIndependent statistical analysis of Dose Ranging Study of Amlitelimab in Adult Participants With Moderate-to-severe Asthma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…Phase 2Results postedn = 437NCT05421598
• TitAINIndependent statistical analysis of A Placebo-controlled Phase 2 Trial to Investigate the Safety and Efficacy of Secukinumab in Giant Cell Arteritis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…Phase 2Results postedn = 52NCT03765788
• TN07Independent statistical analysis of Oral Insulin for Prevention of Diabetes in Relatives at Risk for Type 1 Diabetes Mellitus: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…Phase 3Results postedn = 560NCT00419562
• TOSCAIndependent statistical analysis of A Study of Tocilizumab (RoActemra) in Tocilizumab-Naive Participants With Rheumatoid Arthritis and Inadequate Response to Non-Biologic Disease-Modifying Antirheumatic Drugs (DMARDs) and/or Biologic Therapy: primary endpoint results, effect estimate…Phase 3Results postedn = 139NCT02001987
• TPMIIndependent statistical analysis of Improving Prospective Memory Via Telehealth: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT05129293).Phase NAResults postedn = 35NCT05129293
• TRAILIndependent statistical analysis of Letrozole for Lymphangioleiomyomatosis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01353209).Phase 2Results postedn = 17NCT01353209
• TULIP SLE LTEIndependent statistical analysis of Long Term Safety of Anifrolumab in Adult Subjects With Active Systemic Lupus Erythematosus: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…Phase 3Results postedn = 559NCT02794285

← All therapeutic areas